Cargando…
Investigations of the Kinetics and Mechanism of Reduction of a Carboplatin Pt(IV) Prodrug by the Major Small-Molecule Reductants in Human Plasma
The development of Pt(IV) anticancer prodrugs to overcome the detrimental side effects of Pt(II)-based anticancer drugs is of current interest. The kinetics and reaction mechanisms of the reductive activation of the carboplatin Pt(IV) prodrug cis,trans-[Pt(cbdca)(NH(3))(2)Cl(2)] (cbdca = cyclobutane...
Autores principales: | Liu, Yang, Tian, Hongwu, Xu, Liyao, Zhou, Li, Wang, Jinhu, Xu, Benyan, Liu, Chunli, Elding, Lars I., Shi, Tiesheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888404/ https://www.ncbi.nlm.nih.gov/pubmed/31726728 http://dx.doi.org/10.3390/ijms20225660 |
Ejemplares similares
-
Structure elucidation and quantification of the reduction products of anticancer Pt(iv) prodrugs by electrochemistry/mass spectrometry (EC-MS)
por: Frensemeier, L. M., et al.
Publicado: (2018) -
Pt(IV) Prodrugs with NSAIDs as Axial Ligands
por: Spector, Daniil, et al.
Publicado: (2021) -
Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
por: Li, Xuejiao, et al.
Publicado: (2018) -
An intramolecular photoswitch can significantly promote photoactivation of Pt(iv) prodrugs
por: Deng, Zhiqin, et al.
Publicado: (2021) -
Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs
por: Spector, Daniil, et al.
Publicado: (2022)